Unterehmen auf Watchlist setzen
BioMarin Pharma
ISIN: US09061G1013
WKN: 924801
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

BioMarin Pharma · ISIN: US09061G1013 · PR Newswire (ID: 20241016SF32148)
16 Oktober 2024 02:30PM

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET


SAN RAFAEL, Calif., Oct. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 29, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a general business update.

Dial-in Number 

U.S. / Canada Dial-in Number: 888-596-4144

International Dial-in Number: 646-968-2525

Conference Call ID: 4980126

U.S. / Canada Replay Dial-in Number: 800-770-2030

International Replay Dial-in Number: 609-800-9909

Playback ID: 4980126

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:



Investors     

Media

Traci McCarty   

Marni Kottle

BioMarin Pharmaceutical Inc.   

BioMarin Pharmaceutical Inc.

(415) 455-7558   

(650) 374-2803

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-third-quarter-2024-financial-results-conference-call-and-webcast-on-tuesday-october-29-2024-at-430pm-et-302277174.html

SOURCE BioMarin Pharmaceutical Inc.

Visuelle Wertentwicklung / Kursverlauf · BioMarin Pharma
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2024
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942